Biotech: Page 2


  • Alicia Zhou, CEO, Cancer Research Institute
    Image attribution tooltip
    Permission granted by CRI
    Image attribution tooltip
    Q&A // First 90 Days

    Want better cancer treatments? Make biopharma more like Silicon Valley

    Alicia Zhou brings startup bona fides to the nonprofit Cancer Research Institute to promote defragmentation of the cancer research effort.

    By Sept. 24, 2024
  • Federal Reserve chairman Jerome Powell speaks at a news conference on Sept. 18, 2024.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    What the Fed’s rate cut means for biotech

    Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.

    By Ben Fidler • Sept. 20, 2024
  • drug shopping cart Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Commercialization, marketing and social media

    As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

    By PharmaVoice staff
  • Meg Alexander headshot
    Image attribution tooltip
    Permission granted by Ovid Therapeutics
    Image attribution tooltip

    After epilepsy setback, Ovid charges confidently ahead in CNS

    A promising epilepsy drug Ovid sold to Takeda recently missed the mark in late-stage trials. But Ovid believes it has other novel mechanisms that could deliver a CNS win.

    By Sept. 20, 2024
  • FDA headquarters with sign in foreground
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Getting IND ready — how companies can avoid common traps

    Overpromising, overcommitting and neglecting CMC are a few of the pitfalls that cause sponsors to stumble when submitting a new drug application.

    By Alexandra Pecci • Sept. 18, 2024
  • brain scan
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The hunt for game-changers against the deadliest form of brain cancer

    Treatments for glioblastoma have fallen short in the face of difficult challenges, but the pipeline is full of renewed attempts.

    By Kelly Bilodeau • Sept. 16, 2024
  • Capitol Hill lit up at night
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Biopharma prepares to pivot from China as Biosecure Act advances

    After the House of Representatives passed the Biosecure Act last week, U.S. biotechs could be  forced to cut ties with five Chinese contract partners.

    By Sept. 16, 2024
  • Biotech investment
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Who’s winning in biotech’s tight market?

    Three of the largest fundraising rounds in 2024 show where investors are willing to place their bets in biotech.

    By Sept. 13, 2024
  • Pharmaceutical cartons with the logo for Bristol Myers Squibb's Opdivo rest on a refrigerator shelf.
    Image attribution tooltip

    George Frey/Reuters

    Image attribution tooltip
    Deep Dive

    A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

    Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

    By Jonathan Gardner • Sept. 10, 2024
  • Drug money
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    A new way of determining a drug’s value — with health equity in mind

    Quality-adjusted life years are an important tool to frame a drug’s cost effectiveness, but they leave out other determinants of health. 

    By Sept. 10, 2024
  • A flag flies above the headquarters campus of Eli Lilly
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies

    The deal, which targets metabolic diseases, is one of a few by Big Pharma to develop lncRNA therapies.

    By Sept. 9, 2024
  • Brain disorder
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Huntington’s disease R&D is regaining ground after several disappointments

    Setbacks haven’t stopped advances by biotechs and pharmas working on new drugs for the inherited brain disorder.

    By Kelly Bilodeau • Sept. 9, 2024
  • layoff concept
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    What 3 layoff stories reveal about pharma’s troubles

    The factors driving the industry’s layoffs — and what could help turn the tide.

    By Sept. 6, 2024
  • Pfizer HQ entrance
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip

    A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market

    Results from Vaxcyte’s clinical pneumococcal vaccine study showed the smaller company could take on Pfizer’s legendary blockbuster.

    By Sept. 4, 2024
  • lab pink liquid
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s ‘it’ therapy — a new drug class gaining steam

    More companies are investing in protein degraders, which leverage a unique approach to harnessing the immune system in cancer, neurological diseases and more.

    By Kelly Bilodeau • Sept. 4, 2024
  • test tube dollar
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Is anyone taking the world’s priciest drugs?

    A slew of breakthrough gene therapies won FDA approval in recent years — but high price tags haven’t always yielded big returns.

    By Aug. 30, 2024
  • Wall Street buildings
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Their Alzheimer’s treatment worked — but shares fell anyway

    Cognition Therapeutics touted what the C-suite saw as a promising mid-stage study in Alzheimer’s, but investors read a different story.

    By Aug. 29, 2024
  • gloved hands cutting psilocybin mushrooms growing in a container
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After an FDA rejection, here’s what’s next in the psychedelics pipeline

    By rejecting the first MDMA therapy earlier this month, the FDA signaled to the psychedelic drug sector that the road to approval isn’t clear cut.

    By Aug. 28, 2024
  • AI hallucination medical
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    As pharma’s AI revolution gets underway, ‘hallucinations’ pose a great risk

    While AI, machine learning and large language models can distill huge amounts of information, they sometimes make mistakes. New technologies could rebuild that trust.

    By Aug. 27, 2024
  • mpox vaccine
    Image attribution tooltip
    Mario Tama/ via Getty Images
    Image attribution tooltip

    As a new mpox strain gains ground, a key drug stumbles in the clinic

    Despite the disappointing results, the drug’s developer, Siga Therapeutics, said there’s more to the story.

    By Kelly Bilodeau • Aug. 26, 2024
  • Pill drug money balance
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Will the IRA squash new drugs? Those worries are likely exaggerated, studies say.

    There’s no link between revenue and R&D from smaller biotechs, and that’s where most innovation comes from, according to new studies.

    By Alexandra Pecci • Aug. 22, 2024
  • Workers gather inside BioMarin’s gene therapy manufacturing plant in Novato, California.
    Image attribution tooltip
    Courtesy of BioMarin Pharmaceutical
    Image attribution tooltip

    BioMarin taps Amgen, Roche vets in executive reshuffle

    Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.

    By Jacob Bell • Aug. 22, 2024
  • Image attribution tooltip
    Courtesy of 23andMe
    Image attribution tooltip
    Q&A

    23andMe inches closer to cancer immunotherapy, guided by its genetic database

    Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.

    By Aug. 20, 2024
  • Brain scan pen blood vessel
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients

    A series of executive turnovers at Gain Therapeutics this year precedes important early-stage Parkinson’s results that could change how the disease is treated.

    By Aug. 13, 2024
  • Daniel Vitt on grey backdrop
    Image attribution tooltip
    Permission granted by Immunic Therapeutics
    Image attribution tooltip

    A potential MS ‘game changer’ could bring more safety to the table — even against viruses

    Immunic’s treatment has anti-inflammation, neuroprotection and antiviral effects plus a ‘benign’ safety profile that even seems to lower the risk of COVID-19 infection.

    By Alexandra Pecci • Aug. 13, 2024
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs

    Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.

    By Jacob Bell • Aug. 8, 2024